Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis grade, transfusion dependence, and symptoms in a cohort of patients...
On location

Should Guadecitabine Be the HMA of Choice in Acute Myeloid Leukemia?

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) suggest that this...
On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
On location

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Nearly three-quarters of patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBL) responded to treatment with nivolumab plus brentuximab vedotin, according to findings presented...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...
On location

New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients

Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
On location

Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS

Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...
On location

Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
On location

Isatuximab Combo Improves Progression-Free Survival in Pretreated Myeloma

In an update from the phase III ICARIA-MM trial, researchers reported that the combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide and dexamethasone...
On location

Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia

Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.